Paion

Company
About PAION
Information
Products
Remimazolam
Angiotensin II
Eravacycline
Career
What does PAIONeering mean to us?
What PAIONeers can expect
Job offers
Media and Investors
At a glance
Newsroom
Information on shares
Investorcenter
Corporate Governance
Annual general meeting
2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Contact
Germany
UK
Nordic Countries
Netherlands

Media and Investors
» Newsroom
» Ad-hoc Releases

2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008

04/03/2023

PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults

01/27/2023

PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults

copyright © PAION AG I all rights reserved
Imprint
Privacy Statement
General Terms and Conditions

Heussstraße 25 | 52078 Aachen | Deutschland

Tel.: +49 241 4453-0 | Fax.: +49 241 4453-100 | e-mail: info@paion.com

Company

About PAION +
Information +

Products

Remimazolam +
Angiotensin II +
Eravacycline +

Career

What does PAIONeering mean to us?
What PAIONeers can expect +
Job offers

Media and Investors

At a glance +
Newsroom +
Information on shares +
Investorcenter +
Corporate Governance +
Annual general meeting +

Contact

Germany
UK
Nordic Countries
Netherlands

Cookie Settings

This website uses cookies.

Some of them are essential and required for running the website. Others improve your user experience and may be activated or deactivated at your discretion.

essential
statistics
external media

Accept all Save

Privacy Statement Imprint